NeurAxis (NRXS) versus The Competition Critical Survey

NeurAxis (NASDAQ:NRXS) is one of 76 publicly-traded companies in the “Electromedical equipment” industry, but how does it weigh in compared to its peers? We will compare NeurAxis to similar businesses based on the strength of its institutional ownership, profitability, risk, earnings, analyst recommendations, valuation and dividends.

Insider and Institutional Ownership

11.8% of NeurAxis shares are owned by institutional investors. Comparatively, 45.1% of shares of all “Electromedical equipment” companies are owned by institutional investors. 15.5% of shares of all “Electromedical equipment” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares NeurAxis and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NeurAxis	-594.55%	N/A	-899.27%
NeurAxis Competitors	-184.05%	-38.10%	-2.79%

Analyst Ratings

This is a breakdown of current ratings and price targets for NeurAxis and its peers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeurAxis	0	0	1	0	3.00
NeurAxis Competitors	236	756	2010	98	2.64

As a group, “Electromedical equipment” companies have a potential upside of 27.87%. Given NeurAxis’ peers higher possible upside, analysts plainly believe NeurAxis has less favorable growth aspects than its peers.

Valuation & Earnings

This table compares NeurAxis and its peers gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
NeurAxis	$2.46 million	-$14.63 million	-0.69
NeurAxis Competitors	$985.65 million	$83.22 million	-6.08

NeurAxis’ peers have higher revenue and earnings than NeurAxis. NeurAxis is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Summary

NeurAxis peers beat NeurAxis on 8 of the 12 factors compared.

About NeurAxis

NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome. The company sells its products to healthcare companies, including hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.